ArticleThe Journal of experimental medicine2018
Impact of immunopathology on the antituberculous activity of pyrazinamide.
Article in The Journal of experimental medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.Antimicrobial agents and chemotherapy · 2024Trial
- Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline againstAntimicrobial agents and chemotherapy · 2026Article
- MakingCell insight · 2026Review
- Immortal genome assumption significantly underestimates replication and death rates ofMicrobiology spectrum · 2026Article
- Immortal genome assumption significantly underestimates replication and death rates ofbioRxiv : the preprint server for biology · 2026Article
- Essential role of MHC II in the antitubercular efficacy of pyrazinamide.Antimicrobial agents and chemotherapy · 2026Article
- The Kinetics of Bedaquiline Diffusion in Tuberculous Cavities Open a Window for the Emergence of Resistance.The Journal of infectious diseases · 2025Article
- Factors associated with post-treatment resorption of lung cavities in individuals with first episodes of drug-sensitive cavitary pulmonary tuberculosis in China.BMC infectious diseases · 2025Article
- A Physiologically Relevant In Vitro Model of Nonreplicating Persistent Mycobacterium tuberculosis in Caseum.Current protocols · 2025Article
- Methods and Models for StudyingInternational journal of molecular sciences · 2024Review
- Role of DNA Double-Strand Break Formation in Gyrase Inhibitor-Mediated Killing of Nonreplicating PersistentACS infectious diseases · 2024Article
- Molecular and microbiological methods for the identification of nonreplicating Mycobacterium tuberculosis.PLoS pathogens · 2024Review
- Clinical Significance of Preoperative Pyrazinamide-Containing Therapy in Tuberculous Constrictive Pericarditis.Infection and drug resistance · 2024Article
- Article
- Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023Review
- Colocation of Lipids, Drugs, and Metal Biomarkers Using Spatially Resolved Lipidomics with Elemental Mapping.Analytical chemistry · 2022Article
- Interleukin-13-Overexpressing Mice Represent an Advanced Preclinical Model for Detecting the Distribution of Antimycobacterial Drugs within Centrally Necrotizing Granulomas.Antimicrobial agents and chemotherapy · 2022Article
- A Ginger Root or Plum Model for the Tuberculosis "Granuloma"?American journal of respiratory and critical care medicine · 2021Article
- Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits.Antimicrobial agents and chemotherapy · 2021Article
- Structure,ACS infectious diseases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
In the 1970s, inclusion of pyrazinamide (PZA) in the drug regimen of tuberculosis (TB) patients for the first 2 mo achieved a drastic reduction of therapy duration. Until now, however, the mechanisms underlying PZA's unique contribution to efficacy have remained controversial, and animal efficacy data vary across species. To understand how PZA kills bacterial populations present in critical lung lesion compartments, we first characterized a rabbit model of active TB, showing striking similarities in lesion types and fates to nonhuman primate models deemed the most appropriate surrogates of human TB. We next employed this model with lesion-centric molecular and bacteriology readouts to demonstrate that PZA exhibits potent activity against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.